Cover -- Contents -- Preface -- Chapter 1. Towards rational design of AMPA receptor ligands: an integrated medicinal, computational, biostructural and molecular pharmacological approach -- Chapter 2. From heparin to synthetic antithrombotics. The pentasaccharide story and follow-up -- Chapter 3. A new future for synthesis? -- Chapter 4. Directed evolution of enantioselective enzymes as catalysts in the production of chiral pharmaceuticals -- Chapter 5. At the interface of organic synthesis and biosynthesis -- Chapter 6. What can structure tell us about function in the estrogen receptors? -- Chapter 7. Molecular docking and dynamics simulations in the ligand binding domain of steroid hormone receptors -- Chapter 8. Peroxisome proliferator-activated receptors and reverse endocrinology -- Chapter 9. Biomolecular mass spectrometry related to drug research -- Chapter 10. Chemical and biological diversity in drug discovery -- Chapter 11. Muscarine acetylcholine receptor knockout mice: phenotypical analysis and clinical implications -- Chapter 12. Changes in expression of the orphan G-protein coupled receptor GPR7 in human painful peripheral neuropathies -- Chapter 13. Computational methods for the analysis of molecular diversity -- Chapter 14. Enhancing drug discovery by acquisition of chemical diversity -- Chapter 15. Chemical diversity as a driving force to design and put in practice synthetic strategies leading to combinatorial libraries for lead discovery and lead optimization -- Chapter 16. Beyond G proteins: the role of accessory proteins in G protein-coupled receptor signalling -- Chapter 17. Mechanisms of action of antipsychotic drugs: the role of inverse agonism at the D2 dopamine receptor -- Chapter 18. Agonist channeling of a2-adrenoceptor function -- Chapter 19. Antibacterials as wonder drugs and how their effectiveness is being compromised -- Chapter 20. Pseudomonas aeruginosa quorum sensing: a target for antipathogenic drug discovery -- Chapter 21. Discovery and development of new anti-bacterial drugs -- Chapter 22. Discovery of small molecule insulin mimetics as potential novel antidiabetic agents -- Chapter 23. Expression databases for pharmaceutical lead optimisation -- Chapter 24. New developments in the pharmacology of cannabinoids -- Author index -- Subject index -- Last Page.